Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution.
O'Neill AF, Trobaugh-Lotrario A, Geller JI, Hiyama E, Watanabe K, Aerts I, Fresneau B, Toutain F, Sullivan MJ, Katzenstein HM, Morland B, Branchereau S, Zsiros J, Maibach R, Ansari M. O'Neill AF, et al. Among authors: morland b. EClinicalMedicine. 2024 Feb 15;69:102446. doi: 10.1016/j.eclinm.2024.102446. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38384339 Free PMC article. Review.
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Zsiros J, et al. Among authors: morland b. Lancet Oncol. 2013 Aug;14(9):834-42. doi: 10.1016/S1470-2045(13)70272-9. Epub 2013 Jul 4. Lancet Oncol. 2013. PMID: 23831416 Free PMC article.
Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC).
Cho SJ, Ranganathan S, Alaggio R, Maibach R, Tanaka Y, Inoue T, Leuschner I, de Krijger R, Vokuhl C, Krailo M, Malogolowkin M, Meyers R, Czauderna P, Hiyama E, Ansari M, Morland B, Trobaugh-Lotrario A, O'Neill AF, Rangaswami A, Häberle B, López-Terrada D. Cho SJ, et al. Among authors: morland b. Pediatr Blood Cancer. 2023 Jun 29:e30505. doi: 10.1002/pbc.30505. Online ahead of print. Pediatr Blood Cancer. 2023. PMID: 37384428
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
Failli M, Demir S, Del Río-Álvarez Á, Carrillo-Reixach J, Royo L, Domingo-Sàbat M, Childs M, Maibach R, Alaggio R, Czauderna P, Morland B, Branchereau S, Cairo S, Kappler R, Armengol C, di Bernardo D. Failli M, et al. Among authors: morland b. Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601. Online ahead of print. Hepatology. 2023. PMID: 37729391
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer.
van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2024 May 22. doi: 10.1038/s41591-024-03065-9. Online ahead of print. Nat Med. 2024. PMID: 38778213 No abstract available.
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Abril-Fornaguera J, Torrens L, Andreu-Oller C, Carrillo-Reixach J, Rialdi A, Balaseviciute U, Pinyol R, Montironi C, Haber PK, Del Río-Álvarez Á, Domingo-Sàbat M, Royo L, Akers NK, Willoughby CE, Peix J, Torres-Martin M, Puigvehi M, Cairo S, Childs M, Maibach R, Alaggio R, Czauderna P, Morland B, Losic B, Mazzaferro V, Guccione E, Sia D, Armengol C, Llovet JM. Abril-Fornaguera J, et al. Among authors: morland b. Mol Cancer Ther. 2023 Apr 3;22(4):485-498. doi: 10.1158/1535-7163.MCT-22-0335. Mol Cancer Ther. 2023. PMID: 36780225 Free PMC article.
A joint international consensus statement for measuring quality of survival for patients with childhood cancer.
van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2023 Jun;29(6):1340-1348. doi: 10.1038/s41591-023-02339-y. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322119 Review.
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer.
van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2024 Feb;30(2):603. doi: 10.1038/s41591-023-02651-7. Nat Med. 2024. PMID: 37963955 No abstract available.
Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer.
van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2024 Feb;30(2):605. doi: 10.1038/s41591-023-02753-2. Nat Med. 2024. PMID: 38092898 No abstract available.
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, Zwaan CM, Nysom K, Gerber N, Castellano A, Laureys G, Ladenstein R, Rössler J, Makin G, Murphy D, Morland B, Vaidya S, Thebaud E, van Eijkelenburg N, Tweddle DA, Barone G, Tandonnet J, Corradini N, Chastagner P, Paillard C, Bautista FJ, Gallego Melcon S, De Wilde B, Marshall L, Gray J, Burchill SA, Schleiermacher G, Chesler L, Peet A, Leach MO, McHugh K, Hayes R, Jerome N, Caron H, Laidler J, Fenwick N, Holt G, Moroz V, Kearns P, Gates S, Pearson ADJ, Wheatley K; Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN). Moreno L, et al. Among authors: morland b. J Clin Oncol. 2024 Apr 1;42(10):1135-1145. doi: 10.1200/JCO.23.00458. Epub 2024 Jan 8. J Clin Oncol. 2024. PMID: 38190578 Free article. Clinical Trial.
178 results